Delving into the Latest Updates on AR vaccine(Madison Vaccines, Inc.) with Synapse

The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly diagnosed prostate cancer scheduled to undergo prostatectomy. Patients without evidence of metastatic disease, with tissue remaining from a pre-treatment biopsy, and who are being considered for standard treatment by prostatectomy, will be invited to participate and will be on study for up to 15 months.

Start Date16 Dec 2021

Sponsor / Collaborator

University of Wisconsin Madison

[+5]

NCT04090528 / Active, not recruitingPhase 2

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a maximum of 2 years (32 cycles) or until radiographic progression) on the treatment of castrate-resistant, metastatic prostate cancer. The hypothesis to be tested is that delivering two vaccines with PD-1 blockade will elicit a greater frequency and magnitude of tumor-directed CD8+ T cells, and thereby increase the percentage of patients experiencing objective anti-tumor effect as measured by PSA declines and/or objective radiographic responses. Participants must be 18 years of age or older and can expect to be on treatment for 2 years (32 cycles) and on study for up to 7 years (including 5 years of follow up via phone).

Start Date21 Oct 2019

Sponsor / Collaborator

University of Wisconsin Madison

[+3]

NCT02411786 / CompletedPhase 1

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer

The purpose of this study is to determine if a vaccine called pTVG-AR can enhance the participant's immune response against prostate cancer.

Start Date24 Aug 2015

Sponsor / Collaborator

University of Wisconsin Madison

[+1]

100 Clinical Results associated with AR vaccine(Madison Vaccines, Inc.)

Login to view more data

100 Translational Medicine associated with AR vaccine(Madison Vaccines, Inc.)

Login to view more data

100 Patents (Medical) associated with AR vaccine(Madison Vaccines, Inc.)

Login to view more data

1,022

Literatures (Medical) associated with AR vaccine(Madison Vaccines, Inc.)

31 Dec 2024·Drug Delivery

Incompatibility of antimalarial drugs: challenges in formulating combination products for malaria

Article

Author: Sveinbjornsson, Benjamin R ; Gizurarson, Sveinbjorn ; Snorradottir, Bergthora S ; Mhango, Ellen K G

Lipophilic drugs require more advance formulation, especially if the intention is to make solutions or semisolid formulations. This also accounts for most antimalarial drugs. Although some of these antimalarial drugs are soluble in lipid vehicles, few of them, such as lumefantrine (LF), are also poorly soluble in oily vehicles. Trying to dissolve and formulate LF as a liquid formulation together with other antimalarial drugs is, therefore, a major task. When mixed in solution together with artemether (AR), precipitation occurs, sometimes with LF precipitating out on its own, and sometimes with AR precipitating out alongside LF. In this study, it was hypothesized that the use of fatty acids could lead to enhanced solubility in lipid formulation. Addition of the fatty acid solved the dissolution challenges, making LF soluble for over a year at room temperature (21-23 °C); but further research is needed to test the mechanism of action of the fatty acid. In addition, design of experiments (MODDE^® 13) revealed that the amount of fatty acid in the formulation was the only significant factor for LF precipitation.

01 Jun 2024·International Forum of Allergy & Rhinology

Nasal instillation of povidone‐iodine ameliorates ongoing mucosal inflammation in a pre‐sensitized murine model of Der p1‐induced allergic rhinitis

Article

Author: Kang, Jae-Yoon ; Kim, Yong Min ; Choi, Mi-Ra

AbstractBackgroundInterleukin (IL)‐33, when cleaved into smaller fragments by proteases, becomes hyperactive, contributing to allergic inflammation. Povidone‐iodine (PVP‐I) is an iodine‐based compound that exhibits antimicrobial properties and inhibits proteases. This study aimed to investigate whether PVP‐I treatment inhibits IL‐33 cleavage, improves allergic rhinitis (AR) symptoms, and suppresses allergic inflammation in a mouse model.MethodsIn vitro experiments using full‐length recombinant human IL‐33 and allergens, including house dust mites or Dermatophagoides pteronyssinus 1, were conducted using western blotting. Fifty BALB/c mice were divided into five groups: control (CON), AR with phosphate‐buffered saline treatment (AR), PVP‐I treatment (AR + PVP), trans‐epoxysuccinyl‐L‐leucylamido(4‐guanidino)butane (E64) treatment (AR + E64), and dexamethasone treatment (AR + Dexa). Nasal symptom scores, including rubbing and sneezing, were measured. The cytokine levels in the nasal lavage fluid (NLF) and the concentration of immunoglobulins in the blood serum were assessed. Nasal mucosa from each group was used for reverse transcriptase‐polymerase chain reaction (RT‐PCR) and histological analyses were conducted.ResultsPVP‐I treatment reduced nasal symptoms, suppressed allergic inflammation, and decreased the levels of IL‐33, IL‐5, and IL‐13 in the NLF and total immunoglobulin E (IgE) and specific IgE in the serum. Histopathological analysis revealed a reduction in the number of eosinophils and goblet cells in the nasal mucosa of the AR + PVP group when compared to the AR group. RT‐PCR and immunofluorescence staining confirmed the downregulation of genes and proteins associated with allergic inflammation.ConclusionsThese findings suggest that nasal irrigation with PVP‐I may be a promising therapeutic option for managing AR by inhibiting IL‐33 activation and suppressing allergic inflammation.

02 May 2024·Preparative Biochemistry & Biotechnology

Kinetics of dye decolorization using heterogeneous catalytic system with immobilized Achromobacter xylosoxidans DDB6

Article

Author: Harish, B. S. ; Gopal, K. ; Subashkumar, Rathinasamy ; Kowsik Raj, N. ; Thayumanavan, Thangavelu

Textile effluents containing toxic dyes must be treated effectively before discharge to prevent adverse environmental impacts. Traditional physical and chemical treatment methods are costly and generate secondary pollutants. In contrast, biological treatment is a more suitable, clean, versatile, eco-friendly, and cost-effective technique for treating textile effluent. It is well established that indigenous microbial populations present in effluents can effectively degrade toxic dyes. In this regard, Achromobacter xylosoxidans DDB6 was isolated from the effluent sample to decolorize crystal violet (CV), Coomassie brilliant blue (CBB), and alizarin red (AR) by 67.20%, 28.58%, and 20.41%, respectively. The growth parameters of A. xylosoxidans DDB6 in media supplemented with 100 ppm of various dyes were determined using the modified Gompertz growth model. The immobilized cells in calcium alginate beads showed apparent decolorization rate constant of 0.27, 0.18, and 0.13 h^-1 for CV, CBB, and AR, respectively. The immobilized cells in a packed bed reactor with an optimum flow rate of 0.5 mL/min were used to treat 100 ppm of CV with a percentage decolorization of 79.47% after three cycles. Based on the findings, A. xylosoxidans DDB6 could be effectively used for decolorization of various dyes.

100 Deals associated with AR vaccine(Madison Vaccines, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 2	-	National Cancer Institute	-
Prostatic Cancer	Phase 2	-	University of Wisconsin Madison	-
Prostatic Cancer	Phase 2	-	Madison Vaccines, Inc.	-
Metastatic castration-resistant prostate cancer	Phase 1	US	Madison Vaccines, Inc.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02411786 (ESMO2019) Manual	Phase 1	Metastatic Prostate Carcinoma	40	GM-CSF+AR vaccine(Madison Vaccines, Inc.)	(wmoqdvfzas) = none koeebmuroi (jnbxjxtmsi ) View more	Positive	30 Sep 2019